Searched for
DIVIS LABORATORIES
Solar Industries among 5 stocks hitting 52-week highs; surge up to 22% in a monthFive BSE 200 stocks hit fresh 52-week highs on Thursday despite a weak market. Divi’s Laboratories led the pack with a 22% monthly gain.- TVS Motor among 6 stocks hitting 52-week highs; surge up to 35% in a monthSix BSE 100 stocks, including TVS Motor, Paytm and Divi’s Laboratories, hit fresh 52-week highs despite a weak Sensex session, with gains r...
- Paytm among 4 stocks hitting 52-week highs; surge up to 35% in a monthFour BSE 200 stocks, including Paytm, Divi’s Laboratories, AU Small Finance Bank and Bajaj Auto, hit fresh 52-week highs on Tuesday, gainin...
- Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticost...
- Sunil Singhania-backed Abakkus Flexi Cap Fund increases stake in RIL, Vedanta Power and 32 othersSunil Singhania-backed Abakkus Flexi Cap Fund increased its exposure to Reliance Industries, Vedanta Power and 32 other stocks in July. The...
- Titan Company among 4 stocks to hit 52-week highs and surge up to 25% in a month
- How Wipro's Nifty exit shows old warhorse Indian IT is losing charmWipro’s exit from the Nifty 50 and BSE’s inclusion highlight the shifting composition of India’s benchmark index. The move comes as IT stoc...
- BSE’s Nifty50 hot seat may trigger $695 mn inflows. What this means for shareholdersBSE will replace Wipro in the Nifty 50 from September 30, with Nuvama estimating $695 million inflows into BSE and $240 million outflows fr...
- BSE to replace Wipro in Nifty 50 indexIn a notable change effective September 30, BSE shares will enter the Nifty 50 index, taking over Wipro's longstanding position since Janua...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Sunil Singhania-backed Abakkus Small Cap Fund adds Indo-MIM and 2 others, exits Bank of Baroda and Cyient DLMSunil Singhania-backed Abakkus Small Cap Fund added Indo-MIM, Mrs Bectors Food Specialities and BEML to its portfolio in July while exiting...
- Divi's Labs Q1 Results: Net profit rises 66% YoY to Rs 902 crore, revenue up 28%The firm’s revenue from operations meanwhile rose around 28% YoY to Rs 3,080 crore in Q1 FY27, from Rs 2,410 crore reported in the year-ago...
- Concurrent Gainers: 15 stocks rally for five straight sessions, surge up to 20%
- Sun Pharma among 7 stocks to hit 52-week highs & surge up to 20% in a monthSeven BSE 100 stocks, including TVS Motor, Divi's Laboratories and Nestle India, touched fresh 52-week highs as Sensex gained 273 points. T...
- Blue Jet Healthcare among 4 stocks flashing bullish signals, hinting at a possible uptrendOn July 29, four stocks in the Nifty500 appeared on the White Marubozu bullish scanner, according to StockEdge's technical scan data. The W...
- TVS Motor Company among 9 stocks to hit 52-week highs & rally up to 15% in a monthNine BSE 100 stocks scaled fresh 52-week highs despite the Sensex slipping 70 points on Tuesday. Bajaj Auto, Titan, TVS Motor and Divi's La...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Dividend alert! Last day to buy Bharti Airtel, Hero MotoCorp, among 43 stocks for dividend payout worth Rs 1,127As per Sebi's T+1 settlement cycle, investors must buy a company's shares at least one trading day before the record date to ensure the sha...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- Buy, Sell or Hold: Citi recommends buy on Divi’s Laboratories; downgrade HCL Technologies post Q1 resultsBrokerages expressed caution on frontline IT stocks following June quarter earnings. Citi downgraded HCL Technologies to Sell, citing weak ...
Load More
